Product Reports Resources Pricing Login Book a demo

Verisian

Biotech & Life Sciences · London, United Kingdom · Founded 2023

Verisian accelerates drug time to market with the industry's first platform offering real study traceability (CDISC, SDTM, ADaM, TFLs) MoreLess

Verisian is a pioneering startup in the healthcare and pharmaceutical industry, offering a groundbreaking platform designed to accelerate the time it takes to bring new drugs to market. The company serves pharmaceutical companies, biotech firms, and clinical research organizations (CROs) that are involved in the development and approval of new medications. Verisian operates in the clinical trials and drug development market, a critical sector that demands high levels of accuracy, transparency, and speed.

The core of Verisian's business model is its innovative platform, Verisian Tracer, which provides real study traceability and ensures the integrity of clinical trials. This platform allows clients to track every step of their clinical studies in real-time, ensuring complete transparency and faster development cycles. By parsing study code and leveraging advanced technology, Verisian enables clients to understand exactly what happened during a study, thereby enhancing confidence in the trial's results.

Verisian also offers Verisian Builder, a tool that accelerates the clinical trial study build process. This tool provides access to a rich library of pre-approved TFL (Tables, Figures, and Listings) ADaM (Analysis Data Model) derivation modules. These modules automate the derivation process from eCRF (electronic Case Report Forms), SDTM (Study Data Tabulation Model), and ADaM to TFL, making the study build process more efficient. Additionally, Verisian Builder allows for the extraction and virtualization of derivation paths from existing studies, facilitating effortless code reuse and further speeding up the study build process.

Verisian makes money by offering its platform and tools on a subscription basis or through licensing agreements with its clients. This model ensures a steady revenue stream while providing significant value to its clients by reducing the time and cost associated with drug development.

In summary, Verisian is revolutionizing the clinical trials process with its innovative technology, providing unparalleled study traceability and integrity, and significantly accelerating drug time to market.

Keywords: clinical trials, drug development, study traceability, pharmaceutical, biotech, transparency, Verisian Tracer, Verisian Builder, automation, healthcare innovation.

Company overview

Verisian company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2023
Headquarters
London, United Kingdom
Employees
24
Open positions
None listed
Dealroom signal
89.1
client focusb2bsub industryPharmaceuticalsub industryHealth Platformbusiness modelSaaSindustryHealthsectorBiotechnologysectorClinicalsectorTechbiosectorHard TechsectorTechbio Drug DiscoverysectorDigital PharmasectorDT and LSsectoruk is8 digital and technologiessectoruk is8 life sciences

Valuation & funding

Verisian funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SEEDEquity / VC May 2025 $5.6M $22M Undisclosed
SEEDEquity / VC Sep 2023 $1.3M $5.3M Seedcamp
Showing 2 recorded eventsUnlock the complete deal history →

Financials

Workforce over time

Available workforce history. Financial fields without reported data are omitted.

YearEmployees
2026 24
2025 15
2024 8
2023 5
Company filings, research estimates and Dealroom dataOpen the full financial model →

Growth signals

Verisian website traffic

Latest recorded traffic for Verisian is 270 monthly website visits, down 67.9% over the last three months. Verisian's team grew 60% over the past year.

Latest monthly visits270 3-month web change-67.9% 1-year team growth+60%
Monthly website visits35 observations · Jul 2023–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Verisian compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Verisian's talent

Book a demo to see the people
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on Verisian's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 1 investor entered at this stage
Other known 2 additional known investors
Cambridge Angels
SuperSeed

Global footprint

Where Verisian has talent and traffic

Workforce by country
5 countries with
team presence
🇬🇧 United Kingdom52.6%
🇮🇹 Italy21.1%
🇩🇪 Germany10.5%
🇮🇳 India10.5%
🇪🇸 Spain5.3%
5 countries shown

In the news

Latest news about Verisian

Recent press, funding announcements, and product moves mentioning Verisian — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Verisian

An AI-synthesized read of the highest-engagement posts about Verisian on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Verisian’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.